Ped-AD – Chillicothe, OH
Chillicothe VAMC 17273 State Route 104, Chillicothe, OH, United StatesThis live activity will cover treating and managing atopic dermatitis in pediatric and adolescent patients.
12 events found.
DB-20-03L Diabetes CARES Grand Rounds – Miami, FL
This activity will cover the treatment and management of patients with type 2 diabetes mellitus (T2DM).
Ped-AD
This live activity will cover treating and managing atopic dermatitis in pediatric and adolescent patients.
DB-20-03L Diabetes CARES Grand Rounds – Wilkes Barre, PA
This activity will cover the treatment and management of patients with type 2 diabetes mellitus (T2DM).
DB-20-03L Diabetes CARES Grand Rounds – Denver, CO
This activity will cover the treatment and management of patients with type 2 diabetes mellitus (T2DM).
CDK 4/6 Inhibitors in HR+/HER2- Breast Cancer – Brooklyn, NY
Black Nurses Association of Greater Houston 6436 Fannin St, Houston, TX, United StatesThis program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.
Sleep GR – Hawthorne, CA
This live activity will cover treating and managing patients with sleep-related disorders.
DB-20-03L Diabetes CARES Grand Rounds – Jamaica, NY
This activity will cover the treatment and management of patients with type 2 diabetes mellitus (T2DM).
Ped-AD
This live activity will cover treating and managing atopic dermatitis in pediatric and adolescent patients.
Rethinking HCC – Nashville, TN
Meharry Medical College 1005 Dr. D.B.Todd Jr. Blvd, Nashville, TN, United StatesThis live activity is focused on treatment strategies for patients with hepatocellular carcinoma (HCC).
Rethinking HCC – Yonkers, NY
This live activity is focused on treatment strategies for patients with hepatocellular carcinoma (HCC).
CDK 4/6 Inhibitors in HR+/HER2- Breast Cancer – Elizabeth, NJ
Trinitas Regional Medical Center 225 Williamson Street, Elizabeth, NJ, United StatesThis program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.